Cambridge Investment Research Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21,100	Closed	-$112K	–	1855
2016 Q3	$112K	Buy	21,100 +3,000	+17%	+$16.2K	﹤0.01%	1666
2016 Q2	$120K	Buy	18,100 +5,000	+38%	+$28K	﹤0.01%	1465
2016 Q1	$61K	Hold	13,100	–	–	﹤0.01%	1547
2015 Q4	$66K	Buy	+13,100	New	+$62.2K	﹤0.01%	1518

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cambridge Investment Research Advisors's KERX Position: Q4 2016 in Review

Cambridge Investment Research Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2016, closing a stake of 21,100 shares — an estimated $112K sold.

Cambridge Investment Research Advisors first reported a position in KERX in Q4 2015 and held it in 4 quarters. The position peaked at $120K in Q2 2016. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

Cambridge Investment Research Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Cambridge Investment Research Advisors sold 21,100 Keryx Biopharmaceuticals Inc shares in Q4 2016, an estimated $112K.
Cambridge Investment Research Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 4 quarters.
Cambridge Investment Research Advisors's Keryx Biopharmaceuticals Inc position peaked at $120K in Q2 2016.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.